Back to today’s briefing

Story perspectives

GSK's CEO Celebrates FDA Approval of E. Coli Antibiotic

5/9/2025

50 8

Summary

Story summary

GSK's CEO, Dame Emma Walmsley, celebrated the FDA's green light for Blujepa, a groundbreaking antibiotic designed to combat E. coli-induced urinary tract infections. This innovative treatment seeks to tackle the growing issue of bacterial resistance. GSK is also gearing up to launch more antibiotics for complex UTI cases, with three additional FDA approvals expected soon.

1 of 1

Story summary

GSK's CEO, Dame Emma Walmsley, celebrated the FDA's green light for Blujepa, a groundbreaking antibiotic designed to combat E. coli-induced urinary tract infections. This innovative treatment seeks to tackle the growing issue of bacterial resistance. GSK is also gearing up to launch more antibiotics for complex UTI cases, with three additional FDA approvals expected soon.